香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 之全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何 責 任。 LUYE PHARMA GROUP LTD. 綠葉製藥集團有限公司 （於 百 慕 達 註 冊 成 立 之 有 限 公 司） （股 份 代 號：02186） 須予披露交易及關連交易 關於轉讓南京綠葉25%權 益 及 關 聯 交 易 的 進 一 步 公 告－ 股權轉讓完成 茲提述 綠葉製藥集團有限公司（「本公司」）日期為2025年12月28日 的 公 告，內 容 有 關南京信石建議收購撤資投資者於南京綠葉的25%股權及關聯交易（「公 告」）。 除 文 義 另 有 所 指 外，本 文 所 用 大 寫 詞 彙 與 公 告 所 界 定 者 具 有 相 同 涵 義。 股權轉讓 代價基準 投 資 協 議 項 下 回 購 期 權 並 未 被 觸 發，亦 未 獲 行 使。相 反，股 權 轉 讓 為 綠 葉 方 與 撤 資 股 東 之 間 經 重 新 磋 商 的 ...

Core Viewpoint - Luye Pharma Group's subsidiary, Shandong Luye Pharmaceutical Co., Ltd., plans to transfer 38.5 million H-shares of Boan Biotechnology to Luye Geneora Holding Limited by January 22, 2026, as part of a subscription agreement related to exchangeable preferred shares [1]. Group 1 - Boan Biotechnology's stock price increased by 3.31% to HKD 9.04, with a trading volume of HKD 365 million [1]. - Luye Pharma previously acquired 98% of Boan Biotechnology, integrating it into its system to access its antibody drug pipeline, technology platform, and production assets [1]. - By 2025, Shandong Luye Pharmaceutical Co., Ltd. is expected to hold 70.81% of Boan Biotechnology's shares, positioning Boan as a key vehicle for Luye Pharma's transition from traditional small molecules to biopharmaceuticals [1].

Group 1 - The stock of Luye Pharma Group (博安生物) increased by nearly 5%, reaching HKD 9.12 with a trading volume of HKD 358 million as of the report time [1] - On January 21, Luye Pharma announced that its board was informed by its controlling shareholder, Luye Pharma Group, about a plan to transfer 38.5 million H-shares to the market through its wholly-owned subsidiary, Shandong Luye Pharmaceutical Co., Ltd., on January 22, 2026 [1] - Luye Pharma previously acquired 98% of the shares of Luye Geneora Holding Limited, integrating its antibody drug pipeline, technology platform, and production assets, with Shandong Luye Pharmaceutical Co., Ltd. becoming the core holding entity [1] Group 2 - By 2025, Shandong Luye Pharmaceutical Co., Ltd. is expected to hold 70.81% of Luye Pharma's shares [1] - Luye Pharma serves as a key vehicle for Luye Pharma Group's transition from traditional small molecules to biopharmaceuticals, aiding in the establishment of a dual research and development system for "chemical drugs + biological drugs" [1]

Core Viewpoint - Luye Pharma Group's subsidiary, Shandong Luye Pharmaceutical Co., plans to transfer 38.5 million H-shares of Boan Biotechnology by January 22, 2026, as part of a subscription agreement related to exchangeable preferred shares [1] Group 1: Company Developments - Boan Biotechnology's stock rose nearly 5%, trading at HKD 9.12 with a transaction volume of HKD 358 million [1] - Luye Pharma previously acquired 98% of Boan Biotechnology, integrating its antibody drug pipeline, technology platform, and production assets [1] - By 2025, Shandong Luye Pharmaceutical will hold 70.81% of Boan Biotechnology's shares, positioning Boan as a key vehicle for Luye Pharma's transition from traditional small molecules to biopharmaceuticals [1] Group 2: Strategic Importance - Boan Biotechnology plays a crucial role in Luye Pharma's dual-line R&D system, combining chemical and biopharmaceutical development [1]

Group 1 - The company Boan Biotechnology (06955) announced that its board has been informed by its controlling shareholder, Luye Pharma Group, regarding a subscription agreement related to exchangeable preferred shares [1] - Luye Pharma's wholly-owned subsidiary, Shandong Luye Pharmaceutical Co., Ltd., is set to transfer 38.5 million H-shares to the issuer, Luye Geneora Holding Limited, on January 22, 2026, as part of the proposed transfer [1]

Core Viewpoint - The company Boan Biotechnology (06955) announced that its board has been informed by its controlling shareholder, Luye Pharmaceutical Group, regarding a proposed transfer of 38.5 million H-shares by its wholly-owned subsidiary, Shandong Luye Pharmaceutical Co., Ltd., to the issuer Luye Geneora Holding Limited on January 22, 2026 [1] Group 1 - The controlling shareholder, Luye Pharmaceutical Group, is involved in a share transfer agreement related to exchangeable preferred shares [1] - The proposed transfer involves a significant number of shares, specifically 38.5 million H-shares [1] - The transaction is scheduled to take place on January 22, 2026 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Shandong Boan Biotechnology Co., Ltd. 山東博安生物技術股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6955） 自願性公告 控股股東轉讓股份 本公告由 山東博安生物技術 股份有限公司（「本公司」）自 願 刊 發。 茲提述本公司日期為2026年1月11日之公告（「該公告」），內 容 有 關（其 中 包 括）本 公司控股股東 綠葉製藥集團有限公司（「綠葉製藥」，連 同 其 附 屬 公 司 統 稱「綠 葉 製藥集團」）擬轉讓本公司股本中之H股（「擬議轉讓」）。除 文 義 另 有 所 指 外，本 公 告 所 用 詞 彙 與 該 公 告 所 界 定 者 具 有 相 同 涵 義。 本公司董事會（「董事會」）已 獲 綠 葉 製 藥 集 團 知 會，根 據 與 ...

Core Viewpoint - The company, Luye Pharma Group, has announced an increase in trading volume of its H-shares and confirmed that it is unaware of any reasons for this change, aside from disclosed information regarding the issuance of exchangeable preferred shares [1][2]. Group 1: Share Issuance and Trading - Luye Pharma Group's wholly-owned subsidiary, Luye Geneora Holding Limited, issued exchangeable preferred shares on December 12, 2025, which allow holders to exchange these shares for existing H-shares held by Luye Pharma Group [1][2]. - Following the issuance of the exchangeable preferred shares, an agreement was made to transfer 100.5 million H-shares to a designated custody account to fulfill the exchange rights associated with these shares [2]. - On January 9, 2026, Luye Pharma Group arranged for its subsidiary, Shandong Luye Pharmaceutical Co., Ltd., to transfer 50 million H-shares to the issuer in the market [2]. Group 2: Product Development and Approval - The company's self-developed drug, BA6101 (60mg), has been approved for market launch by Bolivia's National Medicines and Health Technologies Authority (AGEMED) [2][3]. - BA6101 is a biosimilar to the reference drug Prolia®, widely used for the treatment of osteoporosis, and has the same indications as the reference drug [3]. - The development of BA6101 adheres to international guidelines and has demonstrated high similarity in quality, safety, and efficacy compared to the reference drug, with no clinically significant differences [3]. Group 3: Commercialization Strategy - The company plans to commercialize BA6101 in Bolivia and enhance the accessibility of the drug for patients, providing more treatment options [4]. - Strategic partnerships have been established for the commercialization of BA6101 in other Latin American markets, the United States, Southeast Asia, Hong Kong, and Macau [4]. - The company aims to accelerate its international strategy by offering high-quality domestic biopharmaceuticals, including BA6101, to meet global patient treatment needs [4].

Group 1 - The core viewpoint of the news highlights the performance and growth of the Tianhong Innovation Drug ETF (517380), which has seen significant trading activity and net inflows, indicating strong investor interest in the innovative pharmaceutical sector [1] - As of January 8, the Tianhong Innovation Drug ETF reached a new high with a total scale of 1.597 billion yuan and 1.980 billion shares outstanding, reflecting robust market demand [1] - The ETF tracks the Hang Seng Shanghai-Shenzhen Hong Kong Innovation Drug Select 50 Index (HSSSHID), which includes a diverse selection of 50 leading innovative pharmaceutical companies, with a composition of 40% Hong Kong stocks and 60% A-shares [1] Group 2 - Notable achievements in the innovative pharmaceutical sector include Shiyao Group's R&D expenses of 4.185 billion yuan for the first three quarters of 2025, focusing on ADC, GLP-1, and small nucleic acid pipelines, with total authorized amounts exceeding 9.7 billion USD [2] - BeiGene is projected to achieve a profit of 200 million USD in 2025, with expectations of reaching 600-800 million USD in 2026, as several solid tumor drugs enter critical clinical stages [2] - Three Life Sciences has partnered with Pfizer for a 6 billion USD dual antibody licensing deal, receiving an upfront payment of 1.4 billion USD, with 20 clinical studies planned for 2026 [2]

Group 1: Acquisition and Strategic Moves - Eli Lilly announced the acquisition of Ventyx Biosciences for $1.2 billion, with a premium of 62%, to enhance its NLRP3 inhibitor pipeline, expected to complete in the first half of 2026 [1] - Bangyao Biotech appointed Xiang Yu as CEO starting January 1, 2026, who brings 17 years of experience in the pharmaceutical and healthcare sectors, aiming to accelerate the commercialization of CGT pipelines [2] Group 2: Market Performance and Product Approvals - Jingfeng Medical's stock surged over 30% on its first day of trading in Hong Kong, reflecting strong market confidence in its surgical robot technology and global strategy [3] - Luye Pharma's innovative drug Ruoxinlin received acceptance for a new indication application in China, targeting generalized anxiety disorder, with a clinical efficacy rate exceeding 80% [4] - Hansoh Pharmaceutical's Amivantamab was approved for a new indication in combination with chemotherapy for advanced non-small cell lung cancer patients with specific EGFR mutations, reinforcing its position in the EGFR-TKI market [5]